Recent evidence enriches our understanding of the molecular sites of action of cocaine reward and locomotor stimulation. Dopamine transporter blockade by cocaine appears a sufficient explanation for cocaine-induced locomotion. Variation in DAT appears to cause differences in locomotion without drug stimulation. However, previously-held views that DAT blockade was the sole site for cocaine reward have been replaced by a richer picture of multitransporter involvement with the rewarding and aversive actions of cocaine. These new insights, derived from studies of knockout mice with simultaneous deletions and/or blockade of multiple transporters, provide a novel model for the rewarding action of this heavily-abused substance and implicate multiple monoamine systems in cocaine's hedonic activities. Cocaine is a prototypical psychomotor stimulant that increases locomotor activity and elevates mood with rewarding euphoria.
Cocaine is a prototypical psychomotor stimulant that increases locomotor activity and elevates mood with rewarding euphoria. 1 It also produces fearful and jittery aversive effects in many who take it. 2, 3 Cocaine blocks monoamine uptake by neuronal plasma membrane transporters for dopamine (DAT), serotonin (SERT) and norepinephrine (NET), and can also block ligand-and voltage-gated channels with somewhat lower potencies. 4 Understanding the relationships between cocaine's molecular actions and its psychomotor stimulant and aversive properties has remained surprisingly incomplete. This review focuses on recent advances in our understanding of the complex relationships between cocaine's molecular actions and its locomotor stimulant, rewarding and aversive properties.
The 'DAT-is-it' hypothesis drove thinking about cocaine reward for at least a decade, ideas widely linked to Kuhar, Spealman and their colleagues [4] [5] [6] [7] [8] who gathered evidence from structure-activity relationships of transporter-blocking compounds with differential potencies at DAT, SERT and NET. They examined relationships between potencies of these compounds in tests of reward and binding affinities at each of the monoamine transporters. They each identified the best correlations for the rewarding effects of cocaine with DAT blockade. These authors also cited prior work from lesion studies [9] [10] [11] [12] and electrical brain stimulation studies [13] [14] [15] [16] [17] reward mechanisms. These studies in turn built on prior pharmacologic blockade studies [18] [19] [20] [21] [22] that revealed altered psychostimulant self-administration with dopamine depletions or with dopamine receptor blocking drugs.
This 'DAT-is-it' hypothesis was a major motivation for work that resulted in cloning DAT cDNAs, genes and gene variants in our laboratory and others. [23] [24] [25] [26] [27] [28] [29] [30] It drove characterization and study of DAT gene variants in humans 29, and animal models. 54, 55 It led to the production and characterization of DAT-over-and under-expressing and DAT-knockout mice strains. [56] [57] [58] [59] These studies revealed an exquisite DAT-dependence of cocaine's locomotor stimulation. By contrast, they also produced surprising results that refuted the strong 'DAT-is-it' hypothesis of cocaine reward.
Cocaine-induced locomotion: DAT is it
DAT variation in humans and mice links robustly with variation in both baseline locomotion and/or psychostimulant-induced locomotor activities. Three strains of DAT knockout or knockdown mice produced in separate laboratories each have substantially elevated locomotor activities in novel environments. 56, 58, 59 Supranormal levels of locomotor activity remain elevated even after several hours of habituation. When cocaine is administered, wild-type animals display substantial increases in their locomotion that are several times greater than their habituated baseline activity levels. However, DAT knockout mice display no further cocaine-induced increase in activity. 56, 58, 60 Neither SERT nor NET gene knockouts provide any comparable reduction in cocaine-induced locomotion. 60, 61 Knockout mice have a lifetime to adapt to loss of a single gene product, providing cautions in interpretation (see below). Nevertheless, results from these mice clearly
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indicate that DAT is a necessary and principal site for cocaine-induced locomotor stimulation.
Genetic variation at the mouse and human DAT loci also contributes to interesting locomotor phenotypes. Mouse quantitative trait locus (QTL) studies localize a portion of the B×D recombinant inbred strain difference in baseline and psychomotor stimulant-induced locomotion near the DAT locus, while additional variance maps to a second locus that appears to regulate DAT expression. 62 Human DAT gene markers have reproducibly linked with attention deficit hyperactivity disorder (ADHD). 29, [63] [64] [65] [66] [67] [68] DAT polymorphisms can be linked more strongly to the hyperactivity than to the attention deficits in this disorder. 65 Variation in DAT activity is thus a significant contributor to 'baseline' locomotor activity levels, while DAT is absolutely necessary for cocaine-induced locomotor stimulation.
Cocaine, reward and aversion: rich patterns of multitransporter involvement
This simple story for DAT and cocaine locomotion contrasts strikingly with results for rewarding properties of cocaine. We have tested DAT knockout mice in the conditioned place preference (CPP) paradigm 58 that measures preference for an environment paired with a drug. Homozygous DAT knockout mice express perfectly intact cocaine conditioned place preference. Another DAT knockout strain was also rewarded by cocaine in an operant self-administration paradigm. 69 Two strains of DAT knockouts thus provided convincing evidence that DAT was not necessary for cocaine reward, results fatal to any strong version of the 'DATis-it' hypothesis for cocaine reward.
Studies of reward in mice with deletions of the other monoamine transporters at which cocaine acts did not provide any clear alternative single transporter site for cocaine's rewarding actions. Cocaine was no less rewarding in SERT knockouts tested in the CPP paradigm 58 or in NET knockout mice. 61 The failure of any single monoamine transporter gene knockout strain to eliminate cocaine reinforcement and reward thus left open several possible roles for these transporters in cocaine reward/reinforcement in wild-type mice. These even included the possibility that non-transporter molecular sites of cocaine could be involved in cocaine reward/reinforcement. We chose to pursue a different hypothesis: that cocaine normally works as a 'dirty drug', producing rewarding effects through simultaneous actions at more than one transporter site. Multiple molecular sites for cocaine's rewarding/reinforcing actions could provide redundancies so that no one site alone would be absolutely required for cocaine reward. Such redundancies could even be enhanced by compensatory mechanisms active in mice that develop without one or more transporters. If cocaine normally altered activities in several parallel or interactive brain systems with substantial redundancies, the systems expressing the remaining transporter(s) might thus compensate for loss of cocaine-modulated activities in knockout mouse brain systems that normally expressed the absent transporters, maintaining cocaine reward.
We tested whether DAT-and SERT-expressing systems could each provide such redundancy in the longterm absence of the other transporter. We constructed double knockout mice with deletions of both the DAT and SERT genes, examined their baseline behavioral and biochemical features, and tested their preference for cocaine. 60 Deletions of all of the DAT combined with removal of either half or all of the SERT completely eliminated cocaine reward assessed in the CPP paradigm. These results defined, for the first time, a minimal set of gene deletions necessary for elimination of cocaine reward. More recent evidence underscores the specificity of these observations. Double knockouts of both SERT and NET fail to reduce cocaine reward. 70 In fact, SERT/NET double knockouts dramatically enhance cocaine place preference.
While we have thus identified a specific group of sites whose elimination can totally block measures of cocaine reward, we have also identified potential sites for some of the aversive effects reported by cocaine users. Data from reduced or enhanced cocaine reward in the absence of specific transporters or transporter combinations can be tentatively assembled with prior data from other transporter blocking drugs as follows (see also Figure 1 ):
DAT appears to be the transporter most associated with rewarding properties of cocaine in conditioned place preference tests. Compounds with substantial selectivity for DAT can produce place preferences and are self-administered by animals, although often less avidly than cocaine (for review see Rothman and Glowa). 71 However, as noted above, DAT is not 'it', since DAT deletion alone does not eliminate cocaine reward. 58 Data from DAT knockouts are also tempered by results examining the role of SERT and NET in the maintenance of cocaine reward in these mice. The selective SERT blocker fluoxetine and the selective NET blocker nisoxetine both produce strong place preferences in DAT knockouts but not in wild-type mice or in heterozygote mice with one knockout DAT allele, one wild-type DAT allele and half wild-type levels of DAT expression. 70 These data clearly indicate that blockade of SERT or NET can acquire rewarding properties in DAT's lifelong absence. How much DAT removal and how long this removal needs to be carried out to achieve these striking effects remain interesting current questions. The adaptive mechanisms that make fluoxetine and nisoxetine rewarding in DAT knockouts could well contribute to the reward that cocaine confers in DAT knockout mice, since cocaine retains its ability to block both SERT and NET in these animals. Recent reports that the NET blocker roboxetine enhances nucleus accumbens dopamine in DAT knockout but not in wild-type mice 72 could contribute one biochemical substrate for the nisoxetine reward found in DAT knockouts. Such mechanisms may not be relevant for fluoxetine reward, however, since a selective SERT blocker did not increase nucleus accumbens dopamine levels in the same study.
SERT blockade could well contribute to both rewarding and aversive properties of cocaine. Such explanations seem among the most plausible current explanations for otherwise apparently contradictory data that demonstrate: (1) enhanced cocaine reward in SERT knockout mice; 58 (2) enhanced fluoxetine reward in DAT and in NET knockout mice; 70 and (3) ablated cocaine reward in DAT/SERT combined knockout mice. 60 SERT blockade might normally produce a combination of rewarding and aversive features by augmenting serotonin actions at different serotonin receptor subtypes expressed differentially in distinct serotonergic circuits. If these rewarding and aversive features normally balanced each other to produce little net reward or aversion with SERT blockade, fluoxetine or other selective serotonin reuptake inhibitors would display minimal aversion and also little abuse liability in humans, as has been observed. [73] [74] [75] The fluoxetine reward acquired by DAT and by NET knockout mice is consistent with the idea that each of these knockouts shifts the balance between rewarding and aversive serotonergic components, although not necessarily in identical ways.
NET blockade may well contribute less to rewarding and more to aversive properties of cocaine in wildtype animals. These observations are consistent with frequent human clinical self-reports of 'jitteriness' with cocaine use. 76, 77 They accord with evidence for cocaine Molecular Psychiatry aversive features in some animal models. [78] [79] [80] They fit with the failure of mazindol, a widely used combined DAT/NET blocker, to exhibit any striking human clinical abuse liability and with its not-infrequent discontinuation due to jitteriness and sleep disturbances. [81] [82] [83] Caveats: brain changes in knockout mice and cocaine reward The precise neuroadaptive changes that may contribute to the differences in the rewarding consequences of monoamine transporter blockade in single and multiple transporter knockout mice are unknown. The brains of mice of each of these knockout strains appear grossly normal, although the smaller brains of DAT KO mice are consistent with the smaller overall size of these mice. 84 Each single transporter knockout exhibits a distinctive pattern of brain neurochemical rearrangements, 58, 60, 61, 85, 86 many of which can be tentatively linked to homeostatic mechanisms triggered by increased tonic levels of extracellular neurotransmitters. Thus, the DAT knockouts that display enhanced extracellular dopamine levels 56, 87 and reduced DA clearance 56, 87, 88 also display altered levels of expression of dopamine D1, D2 and D3 receptors levels tyrosine hydroxylase, dopamine-modulated neuropeptides, and other features. 89, 90 Microarray studies of mRNA from the brains of DAT and of SERT knockouts also identify dozens of genes whose expression is consistently altered more than two-fold. 91 None of these characterizations provide evidence for large supraadditive knockout influences on any brain neurochemical, microdialysis or gene expression profile when mice with multiple knockouts have been examined to date, however. No current known neurochemical alteration follows the pattern of retained or absent cocaine reward across these multiple knockout strains.
In DAT knockouts, cocaine could also acquire novel properties by modulating dopamine acting as a 'false transmitter' in cells in which it is not synthesized. Since NET has good affinities for dopamine and SERT can even accumulate dopamine with lower affinity, some of the dopamine that is synthesized in dopaminergic neurons of DAT knockout mice could become a 'false transmitter' at adjacent norepinephrine or serotonin terminals. In a similar fashion norepinephrine could be a false transmitter at adjacent dopaminergic or serotonergic terminals in NET knockouts, and/or serotonin a false transmitter in SERT knockout dopamine or norepinephrine terminals. 92, 93 While some false transmission thus seems likely in these knockouts, it seems an unlikely explanation for all of the current data derived from these mice. NET and SERT blockade by cocaine fails to provide the robust enhancements of striatal dopamine efflux in DAT knockouts that would be expected if false transmission were widespread in these mice. 85 Although cocaine and the NET blocker reboxetine do enhance dopamine efflux in the nucleus accumbens of DAT knockouts, rewarding SERT blockade by fluoxetine fails to enhance this dopamine efflux. 72 Further studies will be necessary to define how much of the cocaine, fluoxet-Molecular Psychiatry ine and/or nisoxetine rewarding responses found in DAT knockouts depend on false neurotransmission. Equally plausible explanations for current data include adaptations in circuits such as those that regulate dopamine cell firing rates and dopamine release after cocaine administration.
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Conclusions
Lifelong deletions of DAT, SERT, NET or transporter combinations each distinctively alter the rewarding effects of blocking the remaining transporters. These results are consistent with the idea that cocaine normally works as a dirty drug that provides both rewarding and aversive properties by distinct actions at these three transporters. The combined observations document adaptations that occur in knockout mice. They also tentatively fit with the human abuse liability of a number of widely used drug classes whose members act differentially at these three monoamine transporters. Current data from monoamine transporter knockouts thus provide several novel pathways to thinking about cocaine therapeutics. Drugs that block cocaine's uptake-inhibiting actions at DAT and SERT but allow it to continue to block uptake by NET could provide a possible means for cocaine antagonism at 'rewarding' transporters and continued cocaine action at its 'aversive' sites. Each of the observations summarized above provides new pharmacological routes to dramatically alter the rewarding valences of cocaine.
